Antonio Escartín

Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension

Raju Kapoor, Pei‐Ran Ho, Nolan Campbell et al. · The Lancet Neurology · 2018 · 337 citations · Full text

Life Sciences, Neurology, Pharmacotherapy +14

A one-year follow-up study of the Symbol Digit Modalities Test (SDMT) and the Paced Auditory Serial Addition Test (PASAT) in relapsing-remitting multiple sclerosis: an appraisal of comparative longitudinal sensitivity

Mariana López‐Góngora, Luís Querol, Antonio Escartín · BMC Neurology · 2015 · 124 citations · Full text

Medicine, Neurology, Psychology +17

Placebo-controlled trial of oral laquinimod in multiple sclerosis: MRI evidence of an effect on brain tissue damage

Massimo Filippi, Maria A. Rocca, Elisabetta Pagani et al. · Journal of Neurology Neurosurgery & Psychiatry · 2013 · 113 citations

Life Sciences, Neurology, Neuroscience +17

Epidemiology of NMOSD in Catalonia: Influence of the new 2015 criteria in incidence and prevalence estimates

María Sepúlveda, Marta Aldea, Domingo Escudero et al. · Multiple Sclerosis Journal · 2017 · 100 citations · Full text

Medicine, Neurology, Disease Surveillance +14

Efficacy and Safety of Masitinib in Progressive Forms of Multiple Sclerosis

Patrick Vermersch, Luís Brieva, Robert J. Fox et al. · Neurology Neuroimmunology & Neuroinflammation · 2022 · 67 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17